Skip to content
← All interventions
Longevity compound

Nicotinamide riboside (NR)

Automated longevity evidence pipeline intervention.

Where the science stands

This page summarizes the current human evidence captured in the Longevity Compass database. Result interpretation is conservative and unresolved outcomes remain unknown.

Evidence depth 86 / 100

Research path

From biological idea to human evidence

These stages show different kinds of evidence for Nicotinamide riboside (NR). Moving through them does not mean an intervention is proven to slow aging.

  1. 1

    Biological idea

    Reviewing animal and laboratory research…

  2. 2

    Human testing

    22 direct aging trial links and 29 related trial links tracked. A trial count describes research activity, not benefit.

  3. 3

    What results show

    2 beneficial, 3 neutral and 0 harmful result links interpreted; 27 remain unresolved.

  4. 4

    Still unanswered

    Whether these findings translate into meaningful, lasting healthy-aging benefits in people remains unproven. Longer follow-up and clearer safety and clinical outcomes are needed.

How AgeBeacon evaluates evidence →

Beyond human trials

The bigger longevity story

Loading animal and laboratory evidence…

Animal and cell studies help explain biological plausibility and identify promising directions. They are shown separately and do not increase the human evidence-depth score.

Signals we're watching

What human studies are measuring

Inflammation

2 result(s) are linked, but direction remains unknown.

Cognition

11 result(s) are linked, but direction remains unknown.

Cardiovascular

6 result(s) are linked, but direction remains unknown.

Muscle

4 result(s) are linked, but direction remains unknown.

Physical function

2 beneficial, 2 neutral, 0 harmful and 0 mixed interpreted result(s); 1 remain unknown.

Research depth

Human evidence picture

Evidence depth describes how much relevant human research exists; it is not an efficacy score. Unknown results are not treated as neutral.

22
Direct aging trials
29
Indirect relevant trials
60
Publications linked
13
Results publications

Interpreted results

Beneficial
2
Neutral
3
Harmful
0
Unknown / unresolved
27

Population relevance

Healthy / aging
8
Disease-specific
4

Safety evidence

1

Trials currently identified with safety-result data.

Go to the source

Studies & publications

Inspect the original evidence behind this profile. Links open the trial registry, PubMed or the publication DOI.

Senolytics to Improve Osteoporosis TherapyNCT06018467INTERVENTIONAL · PHASE2 · 120 participants · ACTIVE_NOT_RECRUITINGNAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive ImpairmentNCT03482167INTERVENTIONAL · PHASE1/PHASE2 · 64 participants · COMPLETEDAbsorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+NCT06919328INTERVENTIONAL · NA · 70 participants · RECRUITINGInflammation in COPD and the Effect of Nicotinamide RibosideNCT04990869INTERVENTIONAL · NA · 60 participants · COMPLETEDVIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional SupplementsNCT04994561INTERVENTIONAL · PHASE1 · WITHDRAWNNicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older AdultsNCT03821623INTERVENTIONAL · PHASE2 · 118 participants · RECRUITINGThe Effect of NAD Supplementation on Brain Vascular Health in AgingNCT05483465INTERVENTIONAL · PHASE4 · 214 participants · RECRUITINGIV Administration of ChromaDex's Niagen® as Compared to NAD+NCT06382688INTERVENTIONAL · NA · 53 participants · UNKNOWNBenefits of Nicotinamide Riboside Upon Cognition and SleepNCT05500170INTERVENTIONAL · NA · 50 participants · RECRUITINGSlow Age: Interventions to Slow Aging in HumansNCT05593939INTERVENTIONAL · PHASE2 · 80 participants · COMPLETEDTrial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney DiseaseNCT03579693INTERVENTIONAL · PHASE2 · 26 participants · COMPLETEDA Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older AdultsNCT03562468INTERVENTIONAL · NA · 40 participants · COMPLETEDOh ES, Opoku G, Darvish S, Craighead DH, Ostrow A, Rossman MJ, Steele CN, Struemph T, You Z, Seals DR, Chonchol M, Nowak KL. Sex Differences in Dementia and Mild Cognitive Impairment in Nondialysis CKD. Clin J Am Soc Nephrol. 2026 Mar 1;21(3):389-400. doi: 10.2215/CJN.0000000922. Epub 2025 Nov 20.PMID 41264372Results publicationFreeberg KA, Craighead DH, Martens CR, You Z, Chonchol M, Seals DR. Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults. Front Cardiovasc Med. 2022 May 10;9:881703. doi: 10.3389/fcvm.2022.881703. eCollection 2022.PMID 35620522Results publicationNorheim KL, Ben Ezra M, Heckenbach I, Andreasson LM, Eriksen LL, Dyhre-Petersen N, Damgaard MV, Berglind M, Pricolo L, Sampson D, Dellinger RW, Sverrild A, Treebak JT, Ditlev SB, Porsbjerg C, Scheibye-Knudsen M. Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial. Nat Aging. 2024 Dec;4(12):1772-1781. doi: 10.1038/s43587-024-00758-1. Epub 2024 Nov 15.PMID 39548320Results publicationAhmadi A, Valencia AP, Begue G, Norman JE, Fan S, Durbin-Johnson BP, Jenner BN, Campbell MD, Reyes G, Kapahi P, Himmelfarb J, de Boer IH, Marcinek DJ, Kestenbaum BR, Gamboa JL, Roshanravan B. A Pilot Trial of Nicotinamide Riboside and Coenzyme Q10 on Inflammation and Oxidative Stress in CKD. Clin J Am Soc Nephrol. 2025 Mar 1;20(3):346-357. doi: 10.2215/CJN.0000000624. Epub 2025 Jan 23.PMID 39847432Results publicationAhmadi A, Begue G, Valencia AP, Norman JE, Lidgard B, Bennett BJ, Van Doren MP, Marcinek DJ, Fan S, Prince DK, Gamboa J, Himmelfarb J, de Boer IH, Kestenbaum BR, Roshanravan B. Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease. JCI Insight. 2023 Jun 8;8(11):e167274. doi: 10.1172/jci.insight.167274.PMID 37159264Results publicationNascimento EBM, Moonen MPB, Remie CME, Gariani K, Jorgensen JA, Schaart G, Hoeks J, Auwerx J, van Marken Lichtenbelt WD, Schrauwen P. Nicotinamide Riboside Enhances In Vitro Beta-adrenergic Brown Adipose Tissue Activity in Humans. J Clin Endocrinol Metab. 2021 Apr 23;106(5):1437-1447. doi: 10.1210/clinem/dgaa960.PMID 33524145Results publicationRemie CME, Roumans KHM, Moonen MPB, Connell NJ, Havekes B, Mevenkamp J, Lindeboom L, de Wit VHW, van de Weijer T, Aarts SABM, Lutgens E, Schomakers BV, Elfrink HL, Zapata-Perez R, Houtkooper RH, Auwerx J, Hoeks J, Schrauwen-Hinderling VB, Phielix E, Schrauwen P. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am J Clin Nutr. 2020 Aug 1;112(2):413-426. doi: 10.1093/ajcn/nqaa072.PMID 32320006Results publicationWang DD, Airhart SE, Zhou B, Shireman LM, Jiang S, Melendez Rodriguez C, Kirkpatrick JN, Shen DD, Tian R, O'Brien KD. Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction. JACC Basic Transl Sci. 2022 Sep 14;7(12):1183-1196. doi: 10.1016/j.jacbts.2022.06.012. eCollection 2022 Dec.PMID 36644285Results publicationHendrickx N, Mentre F, Hamdan A, Karlsson MO, Hooker AC, Traschutz A, Gagnon C, Schule R, Synofzik M, Comets E; ARCA Study Group, EVIDENCE-RND consortium. Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score. BMC Med Res Methodol. 2025 Jul 30;25(1):179. doi: 10.1186/s12874-025-02626-x.PMID 40739200Results publicationYulug B, Altay O, Li X, Hanoglu L, Cankaya S, Velioglu HA, Lam S, Yang H, Coskun E, Idil E, Bayraktaroglu Z, Nogaylar R, Ozsimsek A, Yildirim S, Bolat I, Kiliclioglu M, Bayram C, Yuksel N, Tozlu OO, Arif M, Shoaie S, Hacimuftuoglu A, Zhang C, Nielsen J, Turkez H, Boren J, Uhlen M, Mardinoglu A. Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial. Brain Commun. 2025 Jan 6;7(1):fcae478. doi: 10.1093/braincomms/fcae478. eCollection 2025.PMID 39816194Results publicationYulug B, Altay O, Li X, Hanoglu L, Cankaya S, Lam S, Velioglu HA, Yang H, Coskun E, Idil E, Nogaylar R, Ozsimsek A, Bayram C, Bolat I, Oner S, Tozlu OO, Arslan ME, Hacimuftuoglu A, Yildirim S, Arif M, Shoaie S, Zhang C, Nielsen J, Turkez H, Boren J, Uhlen M, Mardinoglu A. Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Transl Neurodegener. 2023 Jan 26;12(1):4. doi: 10.1186/s40035-023-00336-2.PMID 36703196Results publicationZhang SQ, Lee J, Pan JP, Enger R, Hrubos-Strom H, Musiek ES, Fang EF, Le W. NAD+-circadian rhythm coupling in dementia. Alzheimers Dement. 2026 May;22(5):e71360. doi: 10.1002/alz.71360.PMID 42063312Results publication

The big unanswered question

Can promising biology translate into meaningful healthy-aging benefits?

That is the standard this evidence profile is tracking. New trials and results can strengthen, weaken or change the picture over time.

Confidence: moderateScore model: v0.5-curated-ruleUpdated: 2026-09-21Source: live evidence database